Successful Treatment of Bloodstream Infection due to a KPC-Producing Klebsiella Pneumoniae Resistant to Imipenem/Relebactam in a Hematological Patient

Successful Treatment of Bloodstream Infection due to a KPC-Producing Klebsiella Pneumoniae Resistant to Imipenem/Relebactam in a Hematological Patient

Novel carbapenem-β-lactamase inhibitor combination, <i>imipenem/relebactam</i> (IMI-REL), has been recently approved for treatment of infections with limited or no alternative treatment options. In this study, we described the emergence of the IMI-REL-resistance in a KPC-producing <i&...

Full description

Bibliographic Details
Main Authors: Paolo Gaibani, Linda Bussini, Stefano Amadesi, Michele Bartoletti, Federica Bovo, Tiziana Lazzarotto, Pierluigi Viale, Simone Ambretti
Format: Article
Language:English
Published: MDPI AG 2022-04-01
Series:Microorganisms
Subjects:
imipenem/relebactam
meropenem/vaborbactam
cross-resistance
<i>bla</i> <sub>KPC</sub> <sub>-3</sub>
Online Access:https://www.mdpi.com/2076-2607/10/4/778

Similar Items

Similar Items